SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy-Reference-Cited by-同舟云学术

SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy

Published:2018-08-09 Issue:15 Volume:3 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Cassis Paola,Locatelli Monica,Cerullo Domenico,Corna Daniela,Buelli Simona,Zanchi Cristina,Villa Sebastian,Morigi Marina,Remuzzi Giuseppe,Benigni Ariela,Zoja Carlamaria

Funder

AstraZeneca Italia

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/98720/files/pdf

Reference42 articles.

1. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition

2. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease

3. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

4. SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome

5. Mechanisms and Treatment of CKD

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art;American Journal of Cardiovascular Drugs;2024-08-24

2. Clinical value of adding Dapagliflozin in patients with nephrotic syndrome;International Urology and Nephrology;2024-06-12

3. SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake;American Journal of Physiology-Renal Physiology;2024-06-01

4. Renal and systemic hemodynamic effects of empagliflozin: Three randomized, double blind, placebo controlled cross-over trials;2024-05-29

5. Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review;Consilium Medicum;2024-05-20